- €2.57m
- €19.17m
- €33.25m
Brief: Paion Announces Clinical Development Progress With Remimazolam By Partner Hana Pharm In South Korea
Brief: Paion Expects Revenues Of About EUR 3 Mln In 2018
Brief: Paion Starts EU Phase III Trial With Remimazolam In General Anesthesia
Brief: Paion Raises EUR 5.2 Million In Private Placement
Brief: Paion Announces Clinical Development Progress With Remimazolam By Its Partner R-Pharm In Russia
Brief: Paion AG Q1 Net Loss Amounted To EUR 3.1 Mln
Brief: Paion FY Net Loss At EUR 12.1 Million
Brief: PAION Grants Exclusive License To Mundipharma For Development And Commercialization Of Remimazolam In Japan
Brief: PAION announces clinical development progress with remimazolam
Brief: PAION: FDA considers current human abuse liability program with remimazolam in U.S. as sufficient
Brief: PAION 9-mth net loss at 8.5 mln euros
Brief: Paion: Japan patent office grants dosing patent for remimazolam
Brief: PAION granted formulation patent for remimazolam in the EU
Brief: Paion H1 net loss narrows to 5.8 million euros
Brief: Paion: Rr-Pharm starts phase III trial in general anesthesia
Brief: Paion raises 8 mln euros in private placement
Brief: Paion AG says Remimazolam met its primary efficacy endpoint in U.S. Phase III clinical trial
Brief: Paion Q1 revenues at EUR 2.051 mln
Brief: Paion reports positive headline data in US clinical safety trial of Remimazolam